ICCC: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת ImmuCell Corporation

ImmuCell Corporation (ICCC) develops livestock health maintenance products and ensures stable agrologistics through its network of US plants, confirming a market trend visualized in monetary terms with a value of 22.80. The business relies on the implementation of innovative methods to protect calves from diseases without the use of antibiotics. Strict control over vaccine distribution and diversified raw material imports allow the company to seamlessly supply farms with the necessary preparations.

ImmuCell Corporation (ICCC) maintains an impeccable reputation in livestock immunity protection, and the brand trust associated with FirstDefense generates a steady cash flow that underpins the calculation of operating profit. The company's dynamic EV/EBITDA ratio compares the total enterprise value with this profit before taxes and depreciation, allowing investors to determine the premium paid for the asset and assess the balance of market demand.